This research aims to evaluate the long-term disability outcomes associated with different therapies for relapsing-onset multiple sclerosis.
Comparison of platform versus high-efficacy disease-modifying therapies
Evaluation of inflammatory and relapse-independent disability components
Long-term follow-up of disability progression
Differential responses observed in inflammatory and relapse-independent disability components
Support for the need of neuroprotective strategies alongside current therapies
Abstract
Our findings suggest that inflammatory and relapse-independent components of MS disability respond differently to current therapies and highlight the need for complementary neuroprotective strategies.